colorectal-cancer

Better long-read sequencing technology finally distinguishes which Fusobacterium species actually drives colorectal cancer.

Full-length 16S rRNA sequencing using Oxford Nanopore Technology with custom demultiplexing software provides robust species-level discrimination within Fusobacterium, enabling accurate identification of F. animalis (the key CRC driver) vs. F. nucleatum sensu stricto. Validated in whole cells, DNA…

Better long-read sequencing technology finally distinguishes which Fusobacterium species actually drives colorectal cancer.

Key Findings

F. animalis—not F. nucleatum s.s.—primarily drives the CRC-Fusobacterium association
Traditional partial 16S rRNA sequencing cannot distinguish these species
Full-length nanopore 16S sequencing provides reliable species-level discrimination
Method validated in whole cells, DNA mixtures, and clinical CRC specimens
Custom demultiplexing software enables robust taxonomic classification

Implications

Species-level Fusobacterium profiling is essential for mechanistic research and could inform microbiome-based CRC diagnostics.

Caveats

Methodology validation study; abstract-only. The relationship between F. animalis abundance and clinical CRC risk requires further investigation.

Source: Gut microbes — 2026-12-31

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

Better long-read sequencing technology finally distinguishes which Fusobacterium species actually drives colorectal cancer.

Key Findings

Implications

Caveats

Read more

Landmark DCIS trial, CRC microbiome & AML combos

Colorectal Cancer Microbiome Discovery Platform

GBM Tumor Microenvironment Drug Target Atlas

BET Inhibitor Target Selectivity Database